Use of low-molecular-weight heparin to decrease mortality in mice after intracardiac injection of tumor cells

Comparative Medicine

Volumn 59, Issue 1, 2009, Pages 37-45

  Stocking, Kim L ^a   Jones, Jon C ^a   Everds, Nancy E ^a   Buetow, Bernard S ^a,b   Roudier, Martine P ^a   Miller, Robert E ^a  

^a AMGEN INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER RESEARCH; CONTROLLED STUDY; EXPERIMENTAL MOUSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MORTALITY; MOUSE; NONHUMAN; SURVIVAL RATE; THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS; LONGEVITY; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM METASTASIS; THROMBOEMBOLISM; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 63449097209     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. American Cancer Society. [Internet]. Key statistics about bone metastasis: 2007 update [cited 18 Oct 2007]. Available at http://documents. cancer.org/6119.00/6119.00.pdf.
2. Andonegui G, Bonder CS, Green F, Mullaly SC, Zbytnuik L, Raharjo E, Kubes P. 2003. Endothelium-derived Toll-like receptor 4 is the key molecule in LPS-induced neutrophil sequestration into lungs. J Clin Invest 111:1011-1020.
3. Andonegui G, Goyert SM, Kubes P. 2002. Lipopolysaccharide-in- duced leukocyte-endothelial cell interactions: a role for CD14 versus Toll-like receptor 4 within microvessels. J Immunol 169:2111-2119.
4. Andonegui G, Kerfoot SM, McNagny K, Ebbert KVJ, Patel KD, Kubes P. 2005. Platelets express functional Toll-like receptor 4. Blood 106:2417-2423.
5. Arguello F, Baggs RB, Frantz CN. 1988. A murine model of experimental metastasis to bone and bone marrow. Cancer Research 48:6876-6881.
6. Bibby MC. 2004. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. European Journal of Cancer 40:852-857.
7. Everds NE. Hematology of the laboratory mouse. In: Fox JG, Barthold SW, Davisson MT, Newcomer CE, Quimby FW, Smith AL, editors.The mouse in biomedical research, vol. 3. San Diego (CA): Academic Press; 2007. p 133.
8. Hirsh J, Levine MN. 1992. Low-molecular-weight heparin. Blood 79:1-17.
9. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T. 2005. Biolumi- nescent human breast cancer cells lines that permit rapid and sensitive in vivo detection of mammary rumors and multiple metastases in immune deficient mice. Breast Cancer Res 7:R444-R454.
10. Jenkins DE, Oei Y, Hornig YS, Yu SF, Dusich J, Purchio T, Contag PR. 2003. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 20:733-744.
11. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR. 2003. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 20:745-756.
12. Letai A, Kuter DJ. 1999. Cancer, coagulation and anticoagulation. Oncologist 4:443-449.
13. Lip GYH, Chin BSP, Blann AD. 2002. Cancer and the prothrombotic state. Lancet Oncol 3:27-34.
14. Miller FR, Medina D, Heppner GH. 1981. Preferential growth of mammary tumors in intact mammary fatpads. Cancer Research 41:3863-3867.
15. Miller R. 2007. Personal communication.
16. Momi S, Nasimi M, Colucci M, Nenci GG, Gresele P. 2001. Low molecular weight heparins prevent thrombin-induced thromboembolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feedback activation of thrombin generation confers safety advantages over direct thrombin inhibition. Haematologica 86:297-302.
17. Moore DM. Hematology of the mouse. In: Feldman BF, Zinkl, JG, and Jain NC, editors. Schalm's veterinary hematology. Balto (MD): Lippincott, Williams, and Wilkins; 2000. p 1219.
18. Morony S, Capparelli C, Sarosi I, Lacey D, Dunstan CR, Kostenuik PJ. 2001. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432-4436.
19. Mousa SA, Linhardt R, Francis JL, Amirkhosravi A. 2006. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 96:816-821.
20. Mundy GR. 2002. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593.
21. National Research Council. Guide for the care and use of laboratory animals. Washington (DC): National Academic Press; 1996.
22. Paul W, Gresele P, Momi S, Bianchi G, Page CP. 1993. The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits. British Journal of Pharmacology 110:1565-1571.
23. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH. 2003. Animal models of bone metastasis. Cancer 97 Suppl:748- 757.
24. Rubens RD. 1998. Bone metastases-the clinical problem. Eur J Cancer 34:210-213.
25. Sehgal I, Foster TP, Francis J. 2006. Prostate cancer cells show elevated urokinase receptor in mouse model of metastasis. Cancer Cell International 6:21-29.
26. Slofstra SH, Bijlsma MF, Groot AP, Reitsma PH, Lindhout T, ten Cate H, Spek CA. 2007. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood 110:3176-3182.
27. Slofstra SH, van't Veer C, Buurman WA, Reitsma PH, ten Cate H, Spek CA. 2005. Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation. Crit Care Med 33:1365-1370.
28. Smorenburg SM, Van Noorden CJF. 2001. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53:93-105.
29. Tsakiris DA, Scudder L, Hodivala-Dilke K, Hynes RO, Coller BS. 1999. Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost 81:177-188.
30. Vicent S, Luis-Ravelo D, Antón I, García- Tuñón I, Borrás-Cuesta F, Dotor J, De Las Riva J, Lecanda F. 2008. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res 68:2275-2285.
31. Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, Castro-Rivera E, Brekken RA, Gerard RD, Ran S. 2007. Anti- VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. International Journal of Cancer 121:2181-2191.